Close Menu
Home › Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Mar 11, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Natera and BGI Genomics said today that they have signed a $50 million partnership to commercialize Natera's circulating tumor DNA Signatera minimal residual disease (MRD) test in China and to develop reproductive health tests in "select markets," all using BGI's sequencing technology and instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

What's Popular?

In Sequencing

  1. JP Morgan Healthcare Day 2: Abbott, Caris, Danaher, Quest, LabCorp, Luminex, Agilent, Adaptive Bio

  2. Roche, Illumina Partner on Next-Generation Sequencing IVD, CDx Development, Marketing

  3. JP Morgan Healthcare Day 3: Natera, Exact Sciences, Accelerate Dx, GenMark, OraSure, Quidel, Invitae, Opko

  4. Illumina, Genomics England Ink Deal to Sequence up to 300K People

  5. LabCorp Adopts Thermo Fisher's Ion Torrent for CDx Work

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.